Tetroxoprim

Tetroxoprim

Chemical structure of Tetroxoprim

Tetroxoprim is a synthetic antibacterial agent belonging to the class of diaminopyrimidines. It is primarily used in combination with other antibiotics to enhance its efficacy against a broad spectrum of bacterial infections. Tetroxoprim works by inhibiting bacterial dihydrofolate reductase, an enzyme critical for the synthesis of tetrahydrofolate, which is necessary for the production of nucleic acids and ultimately bacterial growth and replication.

Mechanism of Action

Tetroxoprim exerts its antibacterial effects by selectively inhibiting the bacterial enzyme dihydrofolate reductase. This enzyme is responsible for the reduction of dihydrofolic acid to tetrahydrofolic acid, a precursor required for the synthesis of purines, thymidylate, and certain amino acids. By blocking this pathway, tetroxoprim effectively starves the bacteria of the necessary components for DNA synthesis and cell division, leading to bacterial cell death.

Clinical Uses

Tetroxoprim is often used in combination with other antibiotics, such as sulfamethoxazole, to treat a variety of bacterial infections. This combination is particularly effective against urinary tract infections, respiratory tract infections, and certain types of gastrointestinal infections. The synergistic effect of combining tetroxoprim with a sulfonamide enhances the antibacterial spectrum and reduces the likelihood of resistance development.

Pharmacokinetics

Tetroxoprim is well absorbed from the gastrointestinal tract when administered orally. It is widely distributed throughout the body, including penetration into the central nervous system. The drug is metabolized in the liver and excreted primarily in the urine. The half-life of tetroxoprim allows for convenient dosing schedules, often requiring administration only once or twice daily.

Side Effects

Common side effects of tetroxoprim include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. Some patients may experience allergic reactions, including rash and pruritus. Rarely, more severe reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis may occur. As with all antibiotics, there is a risk of Clostridioides difficile infection following treatment.

Resistance

Bacterial resistance to tetroxoprim can occur through several mechanisms, including mutations in the dihydrofolate reductase enzyme that reduce drug binding, increased production of the target enzyme, or acquisition of resistance genes through horizontal gene transfer. The use of tetroxoprim in combination with other antibiotics helps to mitigate the development of resistance.

Related Pages

• Antibiotic resistance
• Dihydrofolate reductase
• Sulfonamides
• Urinary tract infection